申请人:Xiang A. Min
公开号:US20080076753A1
公开(公告)日:2008-03-27
The invention is directed to nonpeptide substituted spiroheterobenzazepine of Formula I,
which are useful as vasopressin receptor antagonists for treating conditions associated with vasopressin receptor activity such as those involving increased vascular resistance and cardiac insufficiency, including congestive heart failure, hyponatremia, and hypertension. Pharmaceutical compositions comprising a compound of Formula I and methods of treating conditions such as hypertension, congestive heart failure, cardiac insufficiency, coronary vasospasm, cardiac ischemia, liver cirrhosis, hyponatremia, renal vasospasm, renal insufficiency, renal failure, diabetic nephropathy, cerebral edema, cerebral ischemia, stroke, thrombosis, or water retention are also disclosed.
该发明涉及公式I的非肽替代螺环杂苯并哌啶,其可用作抗利尿激素受体拮抗剂,用于治疗与利尿激素受体活性相关的情况,如涉及增加血管阻力和心脏功能不全的情况,包括充血性心力衰竭、低钠血症和高血压。还公开了包含公式I化合物的药物组合物以及治疗高血压、充血性心力衰竭、心功能不全、冠脉痉挛、心肌缺血、肝硬化、低钠血症、肾脏痉挛、肾功能不全、肾衰竭、糖尿病肾病、脑水肿、脑缺血、中风、血栓形成或水潴留等疾病的治疗方法。